摘要
目的:探讨不明原因反复流产(URSA)患者Th1/Th2细胞因子失衡关系及淋巴细胞主动免疫治疗的疗效。方法:采用细胞因子体外诱生技术对72例URSA患者和30例正常妇女的外周血单个核细胞进行诱生培养68h后,采用双抗体夹心酶联免疫吸附法检测上清液中的Th1(IFN-γ)和Th2(IL-4)细胞因子水平;URSA患者分为淋巴细胞主动免疫治疗组和常规HCG保胎组,前瞻性研究淋巴细胞主动免疫治疗前后IFN-γ、IL-4细胞因子变化及两组的妊娠结局。结果:URSA患者IL-4水平低于正常对照组(P<0.05),Th1/Th2比值偏向Th1。经主动免疫治疗后,URSA患者IFN-γ水平降低(P<0.05),IL-4水平升高(P<0.05),Th1/Th2比值降低,偏向Th2(P<0.05)。主动免疫妊娠成功率达到85.71%。结论:URSA的发生可能与Th1/Th2平衡失调有关,主动免疫治疗可以有效纠正Th1/Th2平衡失调,对URSA患者是一种有效的治疗方法。
Objective： To explore the imbalance of Thl/Th2 cytokines in patients with unexplained recurrent spontaneous abortion （URSA） and curative effect of active immunotherapy of lymphocytes. Methods： Mononuclear cells in peripheral blood of 72 patients with URSA and 30 normal women were cultured for 68 hours, double antibody sandwich ELISA was used to detect the levels of interferon - γ （ the cytokine of Thl cells） and interleukin- 4 （IL- 4） （the cytokine of Th2 cells） in liquid supernatant ; the patients with URSA were divided into active immunotherapy group and routine human chorionic gonadotropin （HCG） therapy group; the changes of interferon-γ and IL- 4 levels before and ＇after active immunotherapy in active immunotherapy group and pregnancy outcomes in the two groups were researched pro- speetively. Results： IL - 4 level in URSA group was statistically significantly lower than that in normal control group （P 〈 0.05） . The ra- tio of Thl/Th2 deviated to Thl. After active immunotherapy, interferon - γ level in URSA group decreased significantly （ P 〈 0. 05 ） , IL - 4 level increased significantly （ P 〈 0. 05 ） , the ratio of Thl/Th2 decreased and deviated to Th2 （ P 〈 0. 05 ） . The successful rate of pregnancy after active immunotherapy was 85.71%. Conclusion： The occurrence of URSA may be correlated with imbalance of Thl/Th2 cytokines, active immunotherapy can effectively correct imbalance of Thl/Th2, which is an effective method to cure patients with URSA.
出处
《中国妇幼保健》
CAS
北大核心
2013年第5期804-806,共3页
Maternal and Child Health Care of China
关键词
复发性流产
细胞因子
主动免疫
Recun＇ent abortion
Cytokine
Active immunotherapy
